Literature DB >> 8597749

Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Selegeline may be toxic in presence of increased dopamine concentrations.

P H Yu, C T Lai, A A Boulton.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8597749      PMCID: PMC2350556          DOI: 10.1136/bmj.312.7032.703b

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  3 in total

Review 1.  The colorful past and bright future of monoamine oxidase research.

Authors:  T P Singer
Journal:  Prog Brain Res       Date:  1995       Impact factor: 2.453

2.  Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom.

Authors:  A J Lees
Journal:  BMJ       Date:  1995-12-16

3.  Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors.

Authors:  P H Yu; B A Davis; A A Boulton
Journal:  J Med Chem       Date:  1992-10-02       Impact factor: 7.446

  3 in total
  4 in total

1.  Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.

Authors:  A Churchyard; C J Mathias; P Boonkongchuen; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-08       Impact factor: 10.154

2.  Mortality associated with selegiline in Parkinson's disease. What do the available data mean?

Authors:  Y Mizuno; T Kondo
Journal:  Drug Saf       Date:  1997-05       Impact factor: 5.228

3.  MPP(+)-induced toxicity in the presence of dopamine is mediated by COX-2 through oxidative stress.

Authors:  Ya-Ching Hsieh; Ross B Mounsey; Peter Teismann
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-06-12       Impact factor: 3.000

Review 4.  Monoamine oxidase inhibitors. A perspective on their use in the elderly.

Authors:  H P Volz; C H Gleiter
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 4.271

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.